A meta-analysis of SMAD4 immunohistochemistry as a prognostic marker in colorectal cancer

Translational Oncology

Volumn 8, Issue 1, 2015, Pages 18-24

  Voorneveld, Philip W ^a   Jacobs, Rutger J ^a   Kodach, Liudmila L ^a   Hardwick, James C H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

SMAD4 PROTEIN;

ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COLORECTAL CANCER; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; SCORING SYSTEM; TUMOR VOLUME;

EID: 84929927714     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.11.003     Document Type: Article

References (26)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, and Fedewa S, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62, 220–241
2. Riggins GJ, Kinzler KW, Vogelstein B, and Thiagalingam S (1997). Frequency of Smad gene mutations in human cancers. Cancer Res 57, 2578–2580
3. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, and Kinzler KW, et al (1990). Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247, 49–56
4. Salovaara R, Roth S, Loukola A, Launonen V, Sistonen P, Avizienyte E, Kristo P, Järvinen H, Souchelnytskyi S, and Sarlomo-Rikala M, et al (2002). Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut 51, 56–59
5. Alhopuro P, Alazzouzi H, Sammalkorpi H, Davalos V, Salovaara R, Hemminki A, Järvinen H, Mecklin JP, Schwartz Jr S, and Aaltonen LA, et al (2005). SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin Cancer Res 11, 6311–6316
6. Miyaki M, Iijima T, Konishi M, Sakai K, Ishii A, Yasuno M, Hishima T, Koike M, Shitara N, and Iwama T, et al (1999). Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 18, 3098–3103
7. Papageorgis P, Cheng K, Ozturk S, Gong Y, Lambert AW, Abdolmaleky HM, Zhou JR, and Thiagalingam S (2011). Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res 71, 998–1008
8. Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL, and Datta PK (2010). Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology 138, 969–980
9. Langeveld D, van Hattem WA, de Leng WW, Morsink FH, ten Kate FJ, Giardiello FM, Offerhaus GJ, and Brosens LA (2010). SMAD4 immunohistochemistry reflects genetic status in juvenile polyposis syndrome. Clin Cancer Res 16, 4126–4134
10. Hayden JA, Côté P, and Bombardier C (2006). Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144, 427–437
11. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, and Clark GM (2006). Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol 28, 99–105
12. Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, and Ghaneh P (2011). Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer 104, 1440–1451
13. Parmar MK, Torri V, and Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17, 2815–2834
14. Tierney JF, Stewart LA, Ghersi D, Burdett S, and Sydes MR (2007). Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16
15. Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin JP, Hemminki A, Schwartz Jr S, Aaltonen LA, and Arango D (2005). SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 11, 2606–2611
16. Voorneveld PW, Jacobs RJ, de Miranda NF, Morreau H, van Noesel CJ, Offerhaus GJ, Kodach LL, and Hardwick JC (2013). Evaluation of the prognostic value of pSMAD immunohistochemistry in colorectal cancer. Eur J Cancer Prev 22, 420–424
17. Bacman D, Merkel S, Croner R, Papadopoulos T, Brueckl W, and Dimmler A (2007). TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study. BMC Cancer 7, 156
18. Isaksson-Mettävainio M, Palmqvist R, Forssell J, Stenling R, and Oberg A (2006). SMAD4/DPC4 expression and prognosis in human colorectal cancer. Anticancer Res 26, 507–510
19. Mesker WE, Liefers GJ, Junggeburt JM, van Pelt GW, Alberici P, Kuppen PJ, de Miranda NF, van Leeuwen KA, Morreau H, and Szuhai K, et al (2009). Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol 31, 169–178
20. Gulubova M, Manolova I, Ananiev J, Julianov A, Yovchev Y, and Peeva K (2010). Role of TGF-β1, its receptor TGFβRII, and Smad proteins in the progression of colorectal cancer. Int J Colorectal Dis 25, 591–599
21. Li X, Liu B, Xiao J, Yuan Y, Ma J, and Zhang Y (2011). Roles of VEGF-C and Smad4 in the lymphangiogenesis, lymphatic metastasis, and prognosis in colon cancer. J Gastrointest Surg 15, 2001–2010
22. Baraniskin A, Munding J, Schulmann K, Meier D, Porschen R, Arkenau HT, Graeven U, Schmiegel W, Tannapfel A, and Reinacher-Schick A (2011). Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group. Clin Colorectal Cancer 10, 24–29
23. Ahn BK, Jang SH, Paik SS, and Lee KH (2011). Smad4 may help to identify a subset of colorectal cancer patients with early recurrence after curative therapy. Hepatogastroenterology 58, 1933–1936
24. Isaksson-Mettävainio M, Palmqvist R, Dahlin AM, van Guelpen B, Rutegård J, Oberg A, and Henriksson ML (2012). High SMAD4 levels appear in microsatellite instability and hypermethylated colon cancers, and indicate a better prognosis. Int J Cancer 131, 779–788
25. Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, and Papavassiliou AG (2012). Prognostic significance of transforming growth factor beta (TGF-β) signaling axis molecules and E-cadherin in colorectal cancer. Tumour Biol 33, 1005–1014
26. Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, d'Ario G, Cisar L, Labianca R, and Cunningham D, et al (2012). Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 104, 1635–1646.